S-1/A: Impact BioMedical Inc. Files Amendment No. 7 to Form S-1 Registration Statement

Impact BioMedical Inc. has filed an amendment to its Form S-1 registration statement with the SEC, primarily to update information regarding the expenses associated with the issuance and distribution of securities.

Summary

• Impact BioMedical Inc. filed Amendment No. 7 to its Form S-1 registration statement with the Securities and Exchange Commission on August 27, 2024.
• The amendment primarily updates Item 13 of Part II, which details the expenses related to the issuance and distribution of securities.
• The company estimates total expenses of $252,000, including SEC registration fees, FINRA filing fees, NYSE American listing fees, legal and accounting fees, transfer agent fees, and miscellaneous expenses.
• Frank D. Heuszel, Chief Executive Officer, signed the registration statement on behalf of Impact BioMedical Inc.

Sentiment

Score: 7

Explanation: The document is a routine regulatory filing, indicating progress towards a planned public offering. The sentiment is neutral to slightly positive as it reflects forward movement in the company's plans.

Future Outlook

The company plans to commence the proposed sale to the public as soon as practicable after the effective date of the registration statement.

Industry Context

This filing is a standard step for companies preparing to offer securities to the public, ensuring compliance with SEC regulations and providing transparency to potential investors.

Stakeholder Impact

• Potential investors will gain access to Impact BioMedical's securities.
• The company will incur expenses related to the issuance and distribution of securities.

Next Steps

• The SEC will review the registration statement.
• The company will proceed with the public offering after the registration statement becomes effective.

Key Dates

Keywords

S-1, registration statement, securities, issuance, distribution, expenses, Impact BioMedical, SEC